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Abstract 
Hepatocellular carcinoma (HCC) is a highly aggressive and third leading cancer-
related death. PI3k/AKT and p53 signaling pathways play a vital role and regulate cellular 
proliferation, migration, cell cycle, apoptosis, and autophagy during cancer conditions. 
BCL2L12 is a bcl-2 family protein and encoded by the BCL2L12 gene, which is involved in 
the execution phase of apoptosis.  However, the biological function of PI3K/AKT/Bcl-2 
mediated BCL2L12, and its molecular mechanism in HCC is largely unknown. Herein, we 
investigated the effect of Kaempferol, on PI3K/AKT/Bcl-2/BCL2L12 expressions in HCC 
cells. The expression level of PI3K/AKT/Bcl-2/BCL2L12, and its target genes in 
polyphenolic flavonoid Kaempferol treated HCC cells analyzed by Quantitative Real-Time 
PCR and Western blotting. Subsequently, the effect of Kaempferol in HCC chemosensitivity, 
cell proliferation, migration, cell cycle, and apoptosis were analyzed using AO/EtBr staining, 
ROS staining, mitochondrial membrane potential assay, wound healing assay, Transwell 
migration assay, MTT assay, and PI Staining. We found that the downregulation of PI3-K, 
AKT, LC3A/B, MMP9, Bcl-2, and BCL2L12 and upregulation of PTEN, p53, p21, and 
caspase 3 in Kaempferol treated HCC cells. Subsequently, we observed that Kaempferol 
effectively inhibits cellular proliferation, migration and enhances apoptosis, cell cycle arrest, 
autophagy, and 5-Fluorouracil mediated chemosensitivity in HCC cells. Furthermore, 
Kaempferol has dominant role against HCC and inhibits 50-60% of cells after 24h treatment 
with 30μM in HepG2 and 40μM in Huh7 cells. Therefore, Kaempferol plays a promising role 
in cancer therapeutics by inhibiting PI3K/AKT/Bcl-2 mediated BCL2L12 expression in 
HCC. 
Keywords: BCL2L12; Kaempferol; HCC; Apoptosis; Chemosensitivity; PI3K/AKT 
signaling 
Introduction 
Hepatocellular carcinoma (HCC) is a highly aggressive tumor and the third leading 
cause of cancer-related death [1]. Hepatitis B virus (HBV) is the major risk factor for human 
HCC, approximately 50-80 % cases, and the hepatitis C virus (HCV) is 10 to 25 % [2].HCC 
usually diagnosed at the advanced stages, and Chemotherapy is the most frequent treatment 
used for HCC [3].Previous studies revealed that signaling pathways having an important role 
and regulate cell proliferation, cell cycle, apoptosis, and autophagy during carcinogenesis 
especially, Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway 
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and p53 signaling pathway [4]. The p53 is a tumor suppressor (TS) protein [5] encoded by 
the p53 gene, and it is a crucial gene in the prevention of cancer. PI3K/AKT signal 
transduction serves an important role and associated with certain gynaecological tumors [6-
8]. Molecular targets for the PI3K/AKT is the possible way to treat cancer cells.  
B-cell lymphoma 2 (Bcl-2) family consists of pro-apoptotic (BAX, BAK) and anti-
apoptotic (Bcl-2, Bcl-xL, and myeloid cell leukemia-1) proteins that control apoptosis by the 
mitochondrial pathway [9].Bcl2-like 12 (BCL2L12) is a member of the Bcl-2 family and 
encoded by the BCL2L12 gene and which is involved in several cancers [10].The BCL2L12 
role was first discovered in the glioma cancer pathogenesis. BCL2L12 inhibit p53-dependent 
DNA damage-induced apoptosis in glioma [11], and latterly found their role in breast cancer 
[12], Leukemia [13], and Gastric adenocarcinoma (AGS) [14]. The pro-apoptotic gene 
caspase-7 directly and caspase- 3 indirectly regulating the BCL2L12 expressions [15] and 
their enzymes play an important role in the execution phase of apoptosis. Bcl-2 regulated by 
PI3K/AKT in human cancers such as prostate cancer [16] and Breast cancer [17]. 
Kaempferol is a polyphenolic flavonoid present in many plants. Several pre-clinical 
studies have shown that Kaempferol has anticancer and anti-inflammatory effect [18] and 
inhibit invasion and migration in various human cancer cells, such as non-small cell lung 
cancer [29], breast cancer [20], colon cancer [21], and leukaemia [22] and induces apoptosis 
in HepG2 cells [23], and autophagic cell death in SK-HEP-1 human hepatic cancer cells [24]. 
Kaempferol induces apoptosis and cell cycle arrest through the inhibition of PI3K/AKT 
signaling in gastric cancer [25]. Since, the correlation between Kaempferol and 
PI3K/AKT/Bcl-2/BCL2L12 signaling in HCC chemosensitivity, and apoptosis has not 
elucidated. In the present study, we focused to validate the effect of kaempferol on 
PI3K/AKT/Bcl-2mediated BCL2L12proteins in cell cycle, apoptosis, and autophagy 
regulation of HCC cells.  
Materials and methods 
Reagents 
Kaempferol (C15H10O6), 5-FU, and DMSO purchased from Sigma Aldrich Co., St. 
Louis, MO, USA. 2′,7′-Dichlorofluorescin diacetate (DCFH-DA) purchased from Thermo 
Fisher Scientific, Waltham, MA, USA. Dulbecco’s Modified Eagle’s Medium (DMEM), 
Fetal Bovine Serum (FBS), Penicillin Streptomycin and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazoliumbromide (MTT) purchased from HiMedia Laboratories Pvt. Ltd., L.B.S. 
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Marg, Mumbai, MH, IND. Antibodies against BCL2L12, Bcl-2, Caspase 3, PI3K, p-AKT, 
PTEN, p53, p21, and MMP9 purchased from Abcam, Cambridge Science Park Cambridge, 
UK. 
Cell Line, Cell Culture 
Hepatocellular Carcinoma cell line HepG2 and Huh7 purchased from National Centre 
for Cell Science (NCCS), Pune, India. The cells maintained in DMEM supplemented with 
10% FBS and 1%antibiotics. Normal liver epithelial cell line THLE-2 (THLE-2: ATCC- 
CRL- 2706) purchased from American Type Culture Collection (ATCC, Manassas, VA) and 
cultured in Bronchial Epithelial Cell Growth Medium (BMEM) supplemented with 0.08% 
phosphoethanolamine (Sigma Aldrich Co, St. Louis, Missouri, United States), 0.06% human 
recombinant EGF (Corning, NY, USA) and 10% FBS.  All the cells incubated at 37℃ under 
a humidified atmosphere with 5% CO2. 
MTT assay  
HCC cells cultured in 96-well plates, at a concentration of 1x104 cells/well after 
overnight growth, Kaempferol with concentration ranging from 0-60μM dissolved in DMSO 
further incubated for 24h. At the end of treatment 200μl, culture medium containing 20μL 
MTT (5 mg/mL) added to each well and further incubated at 37˚C for 4h. The supernatant 
removed, crystals formations dissolved in 200μl DMSO, and the absorbance measured at 570 
nm using a Microplate reader (Bio Rad, Hercules, CA, USA).  For chemosensitivity, 
following treatment of 24 h, cells harvested and seeded into 96-well plate (5X104). Cells 
treated with the IC50 concentration of 5-fluorouracil for different time intervals (0, 12 and 24 
h). The IC50 values taken from the previous studies for HepG2 cell line (323.2 μM) [26]; 
from Genomics of Drug Sensitivity in Cancer Project for Huh7 cell line (346.49μM). After 
the incubation, the chemosensitivity assay performed by MTT assay, as described in the cell 
proliferation procedure.  
Transwell Migration Assay 
HCC cells (2×105 cells/well) plated in 12-well plates and treated with Kaempferol for 
24 h. Then cells harvested and seeded onto Transwell chamber inserts (with a membrane pore 
size of 8 μM), without Matrigel and DMEM medium placed in the lower chamber for 
overnight. After 16 h incubation, the medium removed and washed with phosphate-buffered 
saline (PBS) twice. Cells fixed with 500 μl of formaldehyde in both well at room temperature 
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(RT) for 2 minutes. After the fixation, inserts washed with PBS twice, and permeabilize cells 
by 100% methanol in inserts and lower well at RT for 20 minutes. After the incubation, 
methanol removed and washed with PBS twice and cells stained with 0.2% crystal violet for 
15 minutes and washed with PBS twice. Non-migrated cells removed from the upper 
chamber by using a cotton swab, and the migrated cells in underside of the filter examined 
and counted using a light microscope at 20X magnification. Stained cells collected by 
washing with 10% acetic acid and quantified by measuring absorbance at 595nm using a 
Microplate reader. 
Wound Healing Assay 
HepG2 and Huh7 cells cultured in 6 well plates at a concentration of 1.5x104 
cells/well and allowed to grow overnight. The next day, cells wounded with help of a sterile 1 
ml pipette tip by dragging it across the monolayer and cells treated with Kaempferol (40 μM) 
for 24h at 37°C. The wound healing process documented at 0h, 12h, and 24h, using a Floid 
cell imaging station and wound gap size or wound area calculated using ImageJ software 
(version.1.8.0). 
Detection of Intracellular ROS 
Measurement of intracellular ROS level in HCC cells made using DCFH-DA staining. 
The cells cultured in 6-well plates at a concentration of 1.5x104cells/well and treated with 
Kaempferol for 24h at 37° C. After treatment, cells incubated with 10μM DCFH-DA in 
Phosphate Buffer Saline (PBS) at 37°C for 30 mins. Later, the intracellular fluorescence 
signal visualized and recorded by Floid cell imaging station. 
Acridine Orange/Ethidium Bromide (AO/EB) staining 
HCC Cells seeded in 6 well culture plates and incubate with Kaempferol for 24 h. 
After treatment, cells stained with 10μl AO/EB (1mg/1ml for 5 minutes) and then visualized 
by Floid cell imaging station (Life Technologies, USA). 
Fluorescent Immunocytochemistry  
HCC cells seeded on a coverslip in six-well plates with a density of 1 × 105 cells per 
ml. After 60% of confluency, cells treated with IC50 (30µM and 40µM for HepG2 and Huh7 
respectively) value of kaempferol. After 24 h incubation, cells fixed with 2% 
paraformaldehyde for 15 min. For permeabilization, cells incubated with 0.2% TritonX-100 
in PBS for 5 min. 3% BSA in PBS used to block the cells. For the detection of BCL2L12, 
 6 
 
cells incubated with an anti-BCL2L12 primary rabbit monoclonal antibody (EPR5201) 
(diluted 1:10,000, Abcam, Cambridge, MA, USA) at 4°C for overnight. Following the 
incubation, cells washed with PBS and stained with goat anti-rabbit Alexa Fluor 647-labeled 
secondary antibody (ab150079-Abcam) for 1 h at RT. For staining of filamentous actin, cells 
incubated with Alexa Fluor 488 phalloidin (Invitrogen) for 30 min at room temperature, and 
cells washed twice with PBS after each step of the staining. Coverslips mounted with 
ProLong Gold Antifade Mountant along with DAPI, and fluorescence images were taken 
using a fluorescence microscope (Carl Zeiss, Jena, Germany). The images captured and 
exported using ImageJ software (NIH). 
Propidium Iodide staining 
HCC cells treated with Kaempferol for 24 h. After the treatment, cells harvested by 
trypsinization and washed with 1x PBS once, and cells fixed with 70% ethanol and stored at 
4˚C for 2 h. After centrifugation, cells washed with PBS and incubated at dark with 
Propidium Iodide (PI) (1.5μg/mL) and RNase (100 U/mL) at 37˚C for 30 minutes. The 
stained cells analyzed by Flow Cytometer. Cytometry data analyzed using FCSalyzer version 
0.9.4.   
Quantitative real-time PCR  
Total RNA isolated using Trizol (Invitrogen, Carlsbad, CA, USA) from control and 
Kaempferol treated HepG2 and Huh7 cells. 2μg of total mRNA reverse transcribed with 
RevertAid First-strand cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA,). 
Quantitative Real-time PCR performed on a Step One Plus RT - PCR (Applied Biosystem, 
Foster City, CA, USA) with sequence-specific primers and SYBER FAST qPCR master mix 
kit (Applied Biosystems) with following concentration: in 10 μl by the Step one plus RT-
PCR (Applied Biosystem): 40 cycles at 95˚C for 15 s, 60˚C for 45 s and 72˚C for 15 s. 
Primers used listed in Supplementary Table 1. Glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH) used for normalization. 
Western blotting 
The cell lysates collected with RIPA lysis buffer (Himedia) (20 mM Tris HCl pH 
8,150 mM NaCl, 0.5 % sodium deoxycholate, 5 mmol/L EDTA, 1 % Nonidet P-40, 0.1 % 
SDS) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich Co). 
The protein sample separated by SDS-PAGE transferred onto a 0.2 μm nitrocellulose 
membrane by transferred apparatus (BioRad Laboratories Incp., Hercules, CA, USA). The 
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membrane blocked using non - fat milk (5 %) in TBS for 1 h at 37 ˚C; washed and proceed at 
primary antibodies (listed in above) overnight at 4˚C. After washing, the membrane incubated 
at alkaline phosphatase (ALP) conjugated anti-rabbit (ab6722) or anti-mouse (ab97020) 
secondary antibody (1:1000; Abcam, Cambridge, MA, USA) and detected by BCIP/NBT 
solution (Merk, Millipore, Bedford, MD, USA). The amount of protein quantified by 
densitometric analysis by using ImageJ software.  
Statistical Analysis 
Statistical analyses performed using GraphPad Prism Software 7.0 (GraphPad 
Software, La Jolla, CA, USA), and the One-way ANOVA performed for comparison. P< 0.05 
considered Significant. All the data presented at least three separate experiments.  
3. Results 
Kaempferol inhibits cellular proliferation and induces 5-Flurouracil mediated 
chemosensitivity in HCC cells 
To understand the cytotoxic effect of Kaempferol, HCC (HepG2 and Huh7) cells 
treated with different concentrations of Kaempferol for 24 h (fig.1.A) and then subjected to 
MTT assay to determine the percent viable cells in post treatment.  The% viable cells 
decreased with the increase of Kaempferol concentration. For further studies, the Kaempferol 
dosage fixed at IC50 of 30μM for HepG2 and 40μM for the Huh7 cell line. Furthermore, 
Kaempferol enhances 5-fluorouracil sensitivity of HCC (HepG2 and Huh7) (Fig. 1.B) cells 
and confirmed by the MTT assay. The chemosensitivity assay showed that the IC50 values of 
5-Fluorouracil decreased significantly due to Kaempferol treatment in HCC cells. 
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Fig.1. Kaempferol inhibits HCC cell viability and enhances Chemosensitivity 
Effect of Kaempferol on HCC (HepG2 and Huh7) cells proliferation (A) and 5-
Flurouracil mediated chemosensitivity (B) by MTT assay. HCC cells treated with 
Kaempferol and then treated with IC50 Value of 5-Fluorouracil (HepG2-323.2 μM; 
Huh7-346.4 μM) and incubated at different time intervals (6 h, 12 h, and 24 h). The 
scale bars represent 100μM. Error bars represent mean ± s.d. and P-values are 
represented as*P< 0.05, **P< 0.01, ***P< 0.001 compared to the corresponding 
controls. 
 
Kaempferol regulates Post-wound migration  
Cell mobility is essential for cancer cell proliferation. Therefore, we investigated the 
effect of Kaempferol on cell proliferation by wound-healing and Transwell migration assay in 
HCC cells. For the wound-healing assay, HepG2 and Huh7 cells treated with Kaempferol, at 
different time intervals (0 h, 12 h, and 24 h). The results showed that cell proliferation 
decreased (50-60%) after the 24 h treatment with Kaempferol in HCC cells when compared 
to control (Fig.2.A).  Next, we assessed the effect of Kaempferol in HCC (HepG2 and Huh7) 
cell migration (Fig.2.B). The transwell migration assay showed that the HCC cell migration 
ability markedly reduced in Kaempferol treated group when compared to the control group. 
Therefore, our result suggests that Kaempferol effectively inhibits the cellular proliferation 
and migration of HCC cells in vitro.  
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Fig.2. Kaempferol inhibits the cell proliferation and migration of HCC cells 
Kaempferol inhibits HCC cell migration in vitro. Scratch assay: HepG2 and Huh7 cell 
lines at 0, 12, and 24 h post-transfection with Kaempferol (A). Gap distance of cells 
was quantified by using Image J. Transwell migration assay (without Matrigel) was 
performed in Kaempferol treated HCC cells (B). The scale bars represent 100μm. 
Error bars represent mean ± s.d. and P-values are represented as ***P< 0.001 
compared to the control. 
 
Kaempferol induces ROS mediated cell death  
To understand the morphological changes in HCC cells induced by Kaempferol treatment, 
Cells stained with AO/EtBr   at 24 h post-treatment with 30 μM (HepG2) and 40 μM (Huh7) 
concentrations. About 50% of cells found to be apoptotic when compared with untreated 
cells. Apoptotic cells appeared orange in Kaempferol treated HCC cells, and there were no 
morphological changes observed in control cells (green) (Fig.3.A). Next, we analyzed the 
ROS generation due to Kaempferol.  After the treatment, DCFH-DA added and examined the 
level of ROS generation. Intracellular ROS generation was significantly higher in 
Kaempferol treated group when compared to the control group (Supplementary Fig.3.B). It 
has shown that Kaempferol rapidly induces the production of intracellular ROS by 
mitochondria and promoting intrinsic apoptosis pathways in HCC cells.  
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Fig.3. Kaempferol induces ROS generation and morphological changes in HCC 
cells 
HCC Cells were stained with AO/EB following the Kaempferol treatment and 
morphological changes were observed. Apoptotic cells appeared orange in Kaempferol 
treated HepG2 and Huh7 cells when compared to control cells (green) (indicated by 
arrows) (A). Intracellular ROS generation was analyzed by ROS staining in 
Kaempferol-treated HCC cells (B). Images were taken using Floid cell imaging station 
(×20). 
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Kaempferol induces cell cycle arrest, and inhibits BCL2L12 protein expression 
Effect of Kaempferol on cell-cycle progression (Fig. 4.A) in HCC cells were studied by 
FACS. After 24 h of Kaempferol treatment, 34.87% of the HCC cells in Sub G0-G1 phase, 
36.19% in G0-G1 phase, 18.2% in S phase and 6.8% in G2 phase when compared to the 
control cells consists of 5.62 % of the HCC cells in Sub G0-G1 phase, 59.35% in G0-G1 
phase, 21.4% in S phase and 10.62% were in G2 phase. Thereby indicating that, Kaempferol 
significantly inhibits cell growth, and induces apoptosis in the Sub G0-G1 phase and cell 
cycle arrest in G0-G1 and G2-M phase in HCC cells. Next, we analyzed the BCL2L12 
protein expression in Kaempferol treated HCC cells by Immunocytochemistry assay.  
BCL2L12 protein expression decreased in Kaempferol treated HCC (HepG2 and Huh7) cells 
when compared to control cells (Fig.4.B). 
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Fig.4. Kaempferol induces cell cycle arrest and inhibits BCL2L12 protein 
expression 
HCC cells were treated with Kaempferol and 24 h later, the effect of Kaempferol on 
cell cycle (A) were determined by flow cytometry using Annexin V-FITC and PI 
staining. Effect of Kaempferol on BCL2L12 Protein expression was analyzed by 
Immunocytochemistry (B). Error bars presented as mean ± s.d. and P-values are 
represented as ***P< 0.001 compared to the control. 
 
BCL2L12 Expression is significantly increased in HCC Cell Lines and Regulated by 
PI3K/AKT/ Bcl-2 signaling 
First, we analyzed the relative expression level of BCL2L12 in HepG2, Huh7, and THLE-2 
cells by qRT- PCR (Fig.5.A) and western blot (Fig.5.B). We observed the overexpression of 
BCL2L12 in HCC (HepG2 and Huh7) cell lines when compared to the normal liver cell line 
(THLE-2). Next, we analyzed the effect of Kaempferol on regulatory genes of apoptosis 
(Bcl-2, Caspase3, and PTEN, BCL2L12), angiogenesis (MMP9) (Fig.5.C-D), cell cycle (p53 
and p21), autophagy (LC3A), and PI3K/AKT signalling (Fig.5.E-F) in HCC cells. The results 
indicated that the BCL2L12, Bcl-2, PI3K, AKT, MMP9, and LC3A/B expression decreased, 
and p53, p21, PTEN, and caspase-3 expression increased in Kaempferol treated HCC cells 
when compared to control. GAPDH used as an internal control. This result showed that 
Kaempferol regulates apoptosis, cell cycle, autophagy, and angiogenesis through targeting 
Bcl-2/PI3K/AKT/BCL2L12 in HCC cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
 
Fig.5. Effect of Kaempferol on apoptosis and angiogenesis regulatory genes  
The relative mRNA (A) and protein (B) expression level of BCL2L12 in HCC (HepG2 
and Huh7) and THLE-2 cells. HCC cells were treated with Kaempferol for 24 h. The 
mRNA (C) and protein (D) expression level of BCL2L12, Bcl-2, Caspase 3, PTEN, 
and MMP9 evaluated by qRT-PCR and western blot. Kaempferol regulates p53, p21, 
PI3K, AKT, and LC3A/B, mRNA (E) and protein (F) levels in HCC cells. GAPDH 
and β-actin were used for normalization. Error bars presented as mean ± s.d and P 
value represented as **P< 0.01, ***P< 0.001, ****P< 0.0001 compared to control. 
 
4. Discussion 
Kaempferol is a flavonoid present in various foods such as apples, strawberries, 
beans, and citrus fruits, some of the major uses of Kaempferol are anti-oxidant and anti-
inflammation, etc. The most important of all is that Kaempferol shows the significant anti- 
cancer activity demonstrated to be effective in inhibiting cell growth and proliferation in 
various cancers [27]. Kaempferol inhibits migration and invasion, reduce MMP2 expression 
and their enzyme activity and also inhibits the ERK1/2 phosphorylation in SCC4 (human 
tongue squamous cell carcinoma) cells [28]. Previous studies have shown that Kaempferol is 
a potential agent for HCC treatment due to its antitumor properties and also inhibit the 
Hep3B cell proliferation [29]. 
In this study, Kaempferol inhibits Bcl-2/PI3K/AKT mediated BCL2L12 expression 
and induces cellular apoptosis by the upregulation of p53 in HCC cells. p53 is a well-known 
tumor suppressor protein, and it works by activating p21.Kaempferol is known to modify 
several upstream regulators of p21 and enhance the phosphorylation of p53 [30]. p21 is a 
highly important checkpoint gene in the cell cycle and regulated by the transcription of p53 
[31]. Rb phosphorylation is a more important target for regulation ofG1/S progression by 
p53. The activation of cyclin kinase inhibitor p21 can, therefore, inhibit Rb phosphorylation 
and prevent E2F transcriptional activity leading to cell cycle arrest in untreated cells [32]. 
The Bcl-2 family members are essential regulators of apoptosis of this BCL2L12, a 
member of the Bcl-2 family, contains several evolutionarily conserved p53-binding sites and 
act as a potent inhibitor of caspase activation and pro-apoptotic activities [33]. BCL2L12 
interacts with p53 and inhibit its binding capacity with their target genes. Thus, BCL2L12 
suppresses the p53 transcription levels after genotoxic stress and inhibit DNA damage-
induced apoptosis and cell cycle arrest activities by downregulation of p53. BCL2L12 
neutralizes the transactivational activity of p53 by inhibiting the binding ofp53 to particular 
target promoters and attenuated p53-mediated induction of selected target genes, including 
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the cell cycle inhibitor p21 and the proapoptotic protein Bax. Besides, Bcl2L12mediates 
neutralization of p53 activity and inhibits DNA damage-induced apoptosis in glioma cells 
[11]. Our result showed that Kaempferol effectively inhibits both G1 and G2 phase 
regulation, cellular proliferation, migration and induced chemosensitivity.  
Subsequent data also showed that PI3K, Akt, Bcl-2, BCL2L12, MMP9, and LC3A/B 
protein expressions were downregulated and PTEN, p53, p21, and Caspase 3 expression 
significantly were upregulated in Kaempferol-treated HCC cells. 
Conclusion 
Kaempferol effectively enhances apoptosis, cell cycle arrest, autophagy, and 
chemosensitivity by targeting PI3K/AKT signaling pathway-dependent Bcl-2/BCL2L12 in 
HCC cells. The multi-functional BCL2L12, an important oncoprotein regulated by 
PI3K/AKT/Bcl-2and acting at the intersection of nuclear p53 and cytoplasmic caspase 
signaling and PI3K/AKT/Bcl-2/BCL2L12 complex could be a promising novel therapeutic 
target for the treatment of HCC. Thus, Kaempferol may act as a potential therapeutic agent 
for the treatment of metastatic HCC. 
Acknowledgement 
We sincerely thank Department of Biotechnology (DBT) for providing financial assistance 
(6242-P49/RGCB/PMD/DBT/AAJV/2015). We also thanks DST-FIST Programme for the 
Instrument facility.  
 
Disclosure of interest 
The authors declare that they have no conflicts of interest concerning this article. 
5. Reference 
1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer 
statistics, CA Cancer J. Clin, 61, 69–90, 2011. 
2. A.M. Di-Bisceglie, Hepatitis B and hepatocellular carcinoma, Hepatology, 49, 56-60, 
2009.  
3. X. Huiying, Y. Zhaoyang, L. Yong, Y. Weigang, Y. Tan, Y. Jia, H. Xingxing, J.L. 
Robert, L. Lei, X. Chuanrui, Delivery of miR-375 and doxorubicin hydrochloride by 
lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug 
resistance in hepatocellular carcinoma, Int. J. of Nano, 12, 5271–5287, 2017. 
4. M. Kannan, S. Jayamohan, R.K. Moorthy, S.C. Chabattula, M. Ganeshan, A.J.V. 
Arockiam, AEG-1/miR-221 Axis Cooperatively Regulates the Progression of 
 15 
 
Hepatocellular Carcinoma by Targeting PTEN/PI3K/AKT Signaling Pathway, Int. J. 
Mol. Sci, 20, 5526-5544, 2019. 
5. D.W. Meek, Regulation of the p53 response and its relationship to cancer, Biochem J 
469, (2015) 325-346. 
6. R. Lu, Z. Yang, G. Xu, S. Yu, miR-338 modulates proliferation and autophagy by 
PI3K/AKT/mTOR signaling pathway in cervical cancer, Biomed. Pharmacother, 105, 
633-644, 2018. 
7. X. Zhang, Y. Zhou, Y.E. Gu, Tanshinone IIA induces apoptosis of ovarian cancer 
cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways, 
Oncol. Lett, 17, 1896-1902, 2019.  
8. S. Jeyamohan, R.K. Moorthy, M.K. Kannan, A.J. Arockiam, Parthenolide induces 
apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in 
cervical cancer, Biotechnol. Lett, 38, 1251-60, 2016. 
9. P. Bose, M. Rahmani, S. Grant, Coordinate PI3K pathway and Bcl-2 family 
disruption in AML,  Oncotarget, 3, 1499-1500, 2012. 
10. A. Fendri, C.K. Kontos, A. Khabir, R. Mokdad-Gargouri, A. Scorilas, BCL2L12 is a 
novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma, 
Mol. Med, 17, 163–171, 2011. 
11. A.H. Stegh, C. Brennan, J.A. Mahoney, K.L. Forloney, H.T. Jenq, J.P. Luciano, A. 
Protopopov, L. Chin, R.A. DePinho, Glioma oncoprotein Bc12L12 inhibits the p53 
tumor suppressor, Genes and Development, 24, 2194–2204, 2010. 
12. S.T. Chien, T.F. Yang, M.C. Yang, C.M. Hsu, Y.R. Hong, T.M. Lee, Differential 
roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis, Oncol. 
Rep, 34, 961-971, 2015. 
13. E.T. Chang, H.O. Adami, The enigmatic epidemiology of nasopharyngeal carcinoma, 
Cancer Epidemiol. Biomarkers Prev, 15, 1765–77, 2006. 
14. A. Giulietti, L. Overberg, D. Valckx, B. Decallonne, R. Bouillon, C. Mathieu, An 
overview of real-time quantitative PCR: applications to quantify cytokine gene 
expression, Methods, 25, 386–401, 2001. 
15. A.H. Stegh, H. Kim, R.M. Bachoo, K.L. Forloney, J. Zhang, H. Schulze, K. Park, G.J. 
Hannon, J. Yuan, D.N. Louis, R.A. DePinho, L. Chin, Bcl2L12 inhibits post 
mitochondrial apoptosis signaling in glioblastoma, Genes. Dev, 21, 98–11, 2007. 
 16 
 
16. N. Torrealba, G. Rodriguez-Berriguete, B. Fraile, G. Olmedilla, P. Martínez-Onsurbe, 
M. Sánchez-Chapado, R. Paniagua, M. Royuela, PI3K pathway and Bcl-2 family. 
Clinicopathological features in prostate cancer, Aging. Male, 21, 211-222, 2018. 
17. M.R. Bratton, B.N. Duong, S. Elliott, C.B. Weldon, B.S. Beckman, J.A. Mclachlan, 
M.E. Burow, Regulation of ERα-mediated transcription of Bcl-2 by PI3K-AKT 
crosstalk: Implications for breast cancer cell survival, Int. J. Oncol, 37, 541–550, 
2010. 
18. W. Ren, Z. Qiao, H. Wang, L. Zhu, L. Zhang, Flavonoids: promising anticancer 
agents, Med. Res. Rev, 23, 519-534, 2003. 
19. S.Q. Liang, T.M. Marti, P. Dorn, L. Froment, S.R. Hall, S. Berezowska, G. Kocher, 
R.A. Schmid, R.W. Peng, Blocking the epithelial-to-mesenchymal transition pathway 
abrogates resistance to anti-folate chemotherapy in lung cancer, Cell Death Dis, 6, 
e1824, 2015. 
20. C. Li, Y. Zhao, D. Yang, Y. Yu, H. Guo, Z. Zhao, B. Zhang, X. Yin, Inhibitory 
effects of kaempferol on the invasion of human breast carcinoma cells by 
downregulating the expression and activity of matrix metalloproteinase-9, Biochem 
Cell Biol, 93, 16-27, 2015. 
21. H.S. Lee, H.J. Cho, G.T. Kwon, J.H. Park, Kaempferol Downregulates Insulin-like 
Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells, 
J. Cancer Prev, 19, 161-169, 2014. 
22. K.Y. Kim, W.Y. Jang, J.Y. Lee, Y. Jun do, J.Y. Ko, Y.H. Yun, Y.H. Kim, 
Kaempferol Activates G(2)-Checkpoint of the Cell Cycle Resulting in G(2)-Arrest 
and Mitochondria- Dependent Apoptosis in Human Acute Leukemia Jurkat T Cells, J. 
Microbiol. Biotechnol, 26, 287-294, 2016. 
23. H. Guo, F. Ren, L. Zhang, X. Zhang, R. Yang, B. Xie, Z. Li, Z. Hu, Z. Duan, J. 
Zhang, Kaempferol induces apoptosis in HepG2 cells via activation of the 
endoplasmic reticulum stress pathway, Mol. Med. Rep, 13, 2791-2800, 2016. 
24. W.W. Huang, S.C. Tsai, S.F. Peng, M.W. Lin, J.H. Chiang, Y.J. Chiu, S. Fushiya, 
M.T. Tseng, J.S. Yang, Kaempferol induces autophagy through AMPK and AKT 
signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in 
SK-HEP-1 human hepatic cancer cells, Int. J. Oncol, 42, 2069-2077, 2013. 
25. H. Song, J. BAO, Y. Wei, Y. Chen, X. Mao, J. Li, Z. Yang, Y. Xue, Kaempferol 
inhibits gastric cancer tumor growth: An in vitro and in vivo study, Oncology Rep, 
33, 868-874, 2015. 
 17 
 
26. F. Pascale, L. Bedouet, M. Baylatry, J. Namur, A. Laurent, Comparative 
Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE, 
ANTICANCER RESEARCH, 35, 6497-6504, 2015. 
27. K. Plochmann, G. Korte, E. Koutsilieri, E. Richling, P. Riederer, A. Rethwilm, P. 
Schreier, C. Scheller, Structure-activity relationships of flavonoidinduced cytotoxicity 
on human leukemia cells, Arch. Biochem. Biophys, 460, 1–9, (2007. 
28. C.W. Lin, P.N. Chen, M.K. Chen, W.E. Yang, C.H. Tang, S.F. Yang, Y.S. Hsieh, 
Kaempferol reduces matrix metalloproteinase-2 expression by down-regulating 
ERK1/2 and the activator protein-1 signaling pathways in oral cancer cells, PLoS 
One, 8, e80883, 2013. 
29. I. Mylonis, A. Lakka, A. Tsakalof, G. Simos, The dietary flavonoid kaempferol 
effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic 
conditions, Biochem. Biophys. Res. Commun, 398, 74-78, 2010. 
30. K. Ito, T.K. Nakazato, T. Yamato, Y. Miyakawa, T. Yamada, N. Hozumi, K. Segawa, 
Y. Ikeda, M. Kizaki, Induction of apoptosis in leukemic cells by homovanillic acid 
derivative, capsaicin, through oxidative stress: Implication of phosphorylation of p53 
at Ser-15 residue by reactive oxygen species, Cancer Research, 64, 1071–1078, 2004. 
31. M. Fischer, M. Quaa, L. Steiner, K. Engeland, p53-p21-DREAM-CDE/CHR pathway 
regulates G2/M cell cycle genes, Nucleic Acids Res, 44, 164-174, 2016. 
32. S. Sheahan, C.O. Bellamy, D.R. Dunbar, D.J. Harrison, S. Prost, Deficiency of G1 
regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFβ cell 
cycle arrest, BMC Cancer, 7, 215, 2007. 
33. H.C. Tu, D. Ren, G.X. Wang, D.Y. Chen, T.D. Westergard, H. Kim, S. Sasagawa, J.J. 
Hsieh, E.H. Cheng, The p53-cathepsin axis cooperates with ROS to activate 
programmed necrotic death upon DNA damage. Proc. Natl. Acad. Sci, 106, 1093-
1098, 2009. 
 
 
 
 
 
 
 
 18 
 
Supplementary Table 1. 
 
 
 
 
 
 
 
 
 
S. 
No 
Gene Forward Primer Reverse Primer 
 
1 BCL2L12 5’CCCTCGGCCTTGCTCTCT-3’ 5’GGGCCACCAAAGCATAGAAG-3’ 
2 PTEN 5’-TGCGGTGACATCAAAGTAGAG-3’ 5’-CTCTGGTCCTGGTATGAAGAATG-3’ 
3 MMP9 5’-CCTGGGCAGATTCCAAACCT-3’ 5’-CAAAGGCGTCGTCAATCACC-3’ 
4 Caspase 3 5’-CAGCTCATACCTGTGGCTGT-3’ 5’-ACTGCTCCTTTTGCTGTGAT-3’ 
5 p53 5’-CCTCTCCCCAGCCAAAGAAG-3’ 5’-TCTCGGAACATCTCGAAGCG-3’ 
6 p21 5’-GTGGCTATTTTGTCCTTGGGCT-3’ 5’-GCGCCTGAACAGAAGAAATCC-3’ 
7 Bcl-2 5’-GTGAACTGGGGGAGGATTGT-3’ 5’-GGAGAAATCAAACAGAGGCC-3’ 
8 PI3K 5’- CCCCTCCATCAACTTCTTCA-3’ 5’-CGGTTGCCTACTGGTTCAAT-3’ 
9 Akt 5’-GGGTTTCTCCCAGGAGGTTT-3’ 5’-GTCCATGGTGTTCCTACCCA-3’ 
10 LC3A 5’-GACTCCATGGCTTCCGAGTT-3’ 5’-GTCCACAGCTGCTTTTCCAC-3’ 
11 GAPDH  5’ATGGGGAAGGTGAAGGTCG-3’ 5’-GGGTCATTGATGGCAACAATATC-3’ 
